Research, Charts & Company Announcements
Research Tree offers CLINIGEN GROUP PLC research coverage from 3 professional analysts, and we have 25 reports on our platform.
Our simple but effective charting function allows for a quick scan of CLINIGEN GROUP PLC's performance over multiple time horizons.
|25/10/2016 07:00:06||London Stock Exchange||BTG partnership extended with new GA agreement|
|24/10/2016 16:00:01||London Stock Exchange||Grant of share options|
|21/10/2016 08:00:06||London Stock Exchange||Issue of Equity|
|20/10/2016 09:51:48||London Stock Exchange||Holding(s) in Company|
|19/10/2016 08:00:02||London Stock Exchange||Director/PDMR Shareholding|
|18/10/2016 07:00:11||London Stock Exchange||Clinigen launches Japanese business|
|12/10/2016 07:00:14||London Stock Exchange||Annual Report and AGM Notice|
Frequency of research reports
Research reports on CLINIGEN GROUP PLC
Providers covering CLINIGEN GROUP PLC
N+1 Singer - Clinigen Group - Strong FY16 delivered, CEO succession in place
28 Sep 16
A strong year has been delivered in line with market expectations, which is a very good achievement given the high level of acquisition related activity the group has undertaken over the last 18 months. This being achieved, it seems a natural time for Peter George to hand the reins over to Shaun Chilton, a move that is not entirely unexpected and should not cause any concern. The outlook remains positive, and trading is reported to be in line with expectations. We do not expect to make any changes to our forecasts at this stage, and reiterate our Buy recommendation and 800p Target Price.
N+1 Singer - Clinigen Group - Strong momentum in H2 likely to continue
21 Jul 16
After some nervousness following a relatively weak H1, a strong H2 has lifted the clouds of uncertainty and added to the share price recovery. Our earnings forecasts are essentially unchanged, but momentum looks strong in the business with a number of potentially positive catalysts on the horizon. We increase our Target Price to 800p (from 735p) and reiterate our Buy recommendation.
N+1 Singer - Clinigen Group - In line FY update reassures
20 Jul 16
A strong H2 brings the FY16 performance in line /slightly ahead, which will support the recent rally in the shares. Revenues were below our expectations, but the more important Gross Profit metric was 2% ahead. There looks to be good momentum in Managed Access and Clinical Trial Supplies in particular. Global Access remains a work in progress, but looks set for an improved FY17. No short term Brexit impact (only 15% of the business is in the UK) and long term should be "manageable". We reiterate our Buy recommendation.
Research on related companies
View the latest research on other companies in the sector, published by expert analysts across the city, at some of the best quality Banks, Brokers, and Independent Providers in the market.
21 Oct 16
STM* (STM): Acquisition of London & Colonial (CORP) | Hurricane Energy (HUR): £70m placing and open offer (BUY) | Firestone Diamonds* (FDI): Liqhobong commissioning update (BUY) | Accsys (AXS): Acorn aiming to be a mighty oak – analyst interview (BUY) | Avacta* (AVCT): Act now… – analyst interview (CORP) | Tristel* (TSTL): Full year 2016 results – analyst interview (CORP)
Panmure Morning Note 27-10-2016
27 Oct 16
CareTech announces that trading to September 2016 is in line with market expectations. The company continues to trade at a significant discount to peers, we believe this is unjustified given the consistent performance in recent periods, including double digit EBITDA growth and high dividend yield. We maintain our BUY recommendation and 380p price target.
25 Oct 16
"London’s blue chip index is called some 15 points higher during this morning’s opening trade, which should see the FTSE-100 test the psychologically important 7000 level once again. The US markets, whose principal indices all closed higher overnight, remain Europe’s main influence as investors track the territory’s latest round of deals and earnings. While broadly pleasing investors, technology issues continue to lead the way which resulted in the NASDAQ registering a full 1% rise on good trading volumes. Against this background, the Federal Reserve Bank of Chicago President, Charles Evans, delivered a speech in which he predicted three US interest-rate rises before the end of 2017, while effectively suggesting that the central bank should allow its inflation target to be overshot before responding with confidence strangling hikes. Generally, however, his forecasts are not far from the current consensus, although he refused to be drawn of the timing of the first move which the markets continue to anticipate in the form of a 25bp move being delivered before the 2016 year-end. By comparison, Asia ended mixed, with the Shanghai Composite finishing unchanged as a weaker Yuan was countered by gains in resource stocks; the latter also boosted the ASX’s commodity-heavy index while a weaker Yen resulted in the Nikkei closing the session with the region’s strongest gain. No major UK macro data are due for release today, which means that traders will eyes will remain focussed on the US disclosure of consumer confidence and housing figures due this afternoon, with neither the ECB President Mario Draghi’s scheduled lecture or the Bank of England Governor, Mark Carney’s appearance before the Lord’s Committee, expected to provide significant new market-sensitive information. Earnings or trading updates are expected from Anglo American Carpetright (AAL.L), GKN (GKN.L), National Express (NEX.L) and Whitbread (WTB.L). Significant quarterly earnings also due from US majors due this afternoon include Apple and General Motors. " - Barry Gibb, Research Analyst
FY 2016 results
17 Oct 16
Full-year results were 7% ahead of the August trading update. Revenue growth of 27% was driven by Vitamin D, up c55%, and sterling's depreciation, which contributed c11% to growth. A higher final dividend together with a 20p special dividend implies a combined yield of 2.9%. Management is confident that Siemens will launch its troponin-based assay contributing to and largely replacing lost NT proBNP royalties in FY 2018. We have increased our target price to 1450p to reflect a 5% EPS upgrade to 2017 earnings and introduced a 2018 forecast, calling for EPS of 72.7p.
N+1 Singer - Morning Song 26-10-2016
26 Oct 16
Verona Pharma has been awarded its second Venture and Innovation Award from the UK Cystic Fibrosis Trust for the development of RPL554 in Cystic Fibrosis (CF). The award signals the significant potential for RPL554 to be developed as a novel treatment for Cystic Fibrosis. Preliminary data supports the molecule’s potential utility in this indication, demonstrating RPL554’S ability to activate an ion channel known to be dysfunctional in CF. The award will support a Phase IIa clinical trial expected to commence in H1 2017. Preparations have also started for Phase IIb trials of RPL554 as a nebulised treatment for COPD with clinical dosing expected to commence in Q2 2017. We remain extremely encouraged by the expanding opportunity of RPL554 and Verona Pharma’s future prospects.